FutureMeds Research Sites in Poland Meet 50% of the COVID-19 Patient Target for Europe and LATAM
Our study teams enrolled 84 patients across three dedicated research sites in Poland, surpassing the enrollment targets, despite operational challenges posed by patient lifestyles and set home visits.
Our dedicated research sites FutureMeds Lodz, FutureMeds Krakow, and FutureMeds Targowek were initiated in late November 2022 and assigned an overall target of enrolling 41 patients in the study that was designed to evaluate the efficacy and safety of a new treatment designed to help mild to moderate COVID-19 patients.
To be able to hit our targets, our dedicated research site teams in collaboration with our patient engagement team implemented an intensive pre-screening process and referral engagement.
This strategy helped us screen 50 patients and successfully enroll 44 patients in a relatively brief 10-week recruitment period. Due to the commitment and approach of our team, we hit a low screen failure rate of 10% and generated a 25% contribution to the Europe and LATAM patient target.
“I am very proud of Renata Cendrowska, Justyna Kurosz, Kinga Zajaczkowska and our teams. Their effort and dedication, and a patient-centric approach lead to outstanding recruitment results in the Covid-19 treatment trial, where almost all visits had to be carried out after working hours, making it very challenging from an operational perspective.”
- Dr Piotr Rozpondek, Managing Director of FutureMeds Poland.
Our team's commitment to quality and patient care was also recognized by the sponsor, who later increased the patient recruitment target to 80 patients.
The team encountered significant operational challenges related to the five home health visits required by the study protocol. These visits had to be conducted by trained research nurses and/or physicians, and there was no "appointment window" for the first three visits. Despite these challenges, our teams were able to complete all home visits as scheduled, with many visits taking place on weekends and over the Christmas period.
“The hardest part was organising a team that would do patient visits after working hours, or on weekends or holidays. Everyone had their own family responsibilities and personal duties so we had to adjust and find a solution together. Our team took whatever time they had to deliver home visits and our doctors often called patients in the evening many hours after their shift had ended. It's a dream team!” - commented Renata Cendrowska, Site Director of FutureMeds Łódź.
On February 24, our study teams exceeded the increased recruitment target of 80 patients: FutureMeds Lodz successfully enrolled 32, FutureMeds Krakow 14, and FutureMeds Targówek 38 patients.
Altogether our teams randomised 84 volunteers. It is a significant contribution and good recruitment is one of the best ways of protecting study timelines.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.